PRISMA-combined Myeloperoxidase -463G/A gene polymorphism and coronary artery disease

Abstract

Background:Myeloperoxidase (MPO) -463G/A gene polymorphism may be associated with an increased risk of developing coronary artery disease (CAD). Studies on the subject, however, do not provide a clear consensus. This meta-analysis was performed to explore the relationship between MPO gene -463G/A polymorphism and CAD risk.Methods:This meta-analysis combines data from 4744 subjects from 9 independent studies. By using fixed or random effect models, the pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were assessed.Results:Our analysis found a significant association between MPO gene -463G/A polymorphism and CAD in the whole population under all genetic models: allelic (OR: 0.68, 95% CI: 0.54–0.85, P = 0.0009), recessive (OR: 0.41, 95% CI: 0.22–0.76, P = 0.005), dominant (OR: 0.682, 95% CI: 0.534–0.871, P = 0.002), homozygous (OR: 0.36, 95% CI: 0.16–0.79, P = 0.01), heterozygous genetic model (OR: 0.832, 95% CI: 0.733–0.945, P = 0.004), and additive (OR: 0.64, 95% CI: 0.46–0.90, P = 0.01), especially in the Chinese subgroup (P < 0.05). On the contrary, we found no such relationship in the non-Chinese subgroup (P > 0.05).Conclusion:The MPO gene -463G/A polymorphism is associated with CAD risk, especially within the Chinese population. The A allele of MPO gene -463G/A polymorphism might protect the people from suffering the CAD risk.

Association between myeloperoxidase rs2333227 polymorphism and susceptibility to coronary heart disease

“…To date there have been no genome-wide association studies relevant to myeloperoxidase rs2333227. Previous meta-analyses [30][31][32][33] garding to myeloperoxidase rs2333227 polymorphism and coronary heart disease gave controversial results. Compared to them, our meta-analysis has some strengths.…”